Version 1
: Received: 25 June 2023 / Approved: 26 June 2023 / Online: 26 June 2023 (10:57:00 CEST)
How to cite:
Moerane, T.; Kama, V. A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase Inhibitor. Preprints2023, 2023061788. https://doi.org/10.20944/preprints202306.1788.v1
Moerane, T.; Kama, V. A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase Inhibitor. Preprints 2023, 2023061788. https://doi.org/10.20944/preprints202306.1788.v1
Moerane, T.; Kama, V. A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase Inhibitor. Preprints2023, 2023061788. https://doi.org/10.20944/preprints202306.1788.v1
APA Style
Moerane, T., & Kama, V. (2023). A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase Inhibitor. Preprints. https://doi.org/10.20944/preprints202306.1788.v1
Chicago/Turabian Style
Moerane, T. and Vuyiswa Kama. 2023 "A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase Inhibitor" Preprints. https://doi.org/10.20944/preprints202306.1788.v1
Abstract
Meningiomas are cerebral cancers that arise from abnormal cell development in the meninges and defensive layers covering the mind and spinal line. They can attack areas close to the cerebrum tissue and apply tension to neighboring designs, prompting different neurological side effects. Recent advances in atomic science and genomics have revealed insights into the fundamental subatomic adjustments and flagging pathways involved in the improvement of meningoma. Cabozantinib, a chemotherapeutic agent, has shown promising results in preclinical and clinical studies in various malignancies, including meningia. It inhibits angiogenesis, reduces cancer development, and prompts cell passage, providing areas of strength for clinical examination. Inhibition of VEGFR2 signaling has shown promise results in clinical trials in various cancer types, including a variety of cancers. This review summarizes the current knowledge on the pathophysiology and potential therapeutic effects of cabozanteb as a therapeutic agent for intracranial meninga.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
